Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders

Best Practice and Research: Clinical Haematology

Volumn 19, Issue 3, 2006, Pages 519-533

  Scott, Bart ^a   Deeg, H Joachim ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

co morbid conditions; cytogenetic risk group; hemopoietic cell transplantation; IPSS score; myelodysplastic syndromes; myelofibrosis; myeloproliferative disorders; organ toxicity; relapse

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; HLA ANTIGEN; IDARUBICIN; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ALLOTRANSPLANTATION; CANCER SURVIVAL; CELL TRANSPLANTATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; DONOR; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC CELL; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALIGNANT TRANSFORMATION; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS;

EID: 33745016073     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.07.009     Document Type: Review

References (69)

1. Greenberg P.L. Myelodysplastic syndrome. In: Hoffman R., Benz E.J., Shattil S.J., Furie B., Cohen H.J., Silberstein L.E., and McGlave P. (Eds). Hematology: Basic Principles and Practice (2000), Churchill Livingstone, New York 1106-1129
2. Sanz G.F., Sanz M.A., Vallespì T., et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74 (1989) 395-408
3. Bennett J.M., Catovsky D., Daniel M.T., et al. The French-American-British (FAB) co-operative group: proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
4. Harris N.L., Jaffe E.S., Diebold J., et al. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
5. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes (erratum appears in Blood Feb 1; 91(3): 1100). Blood 89 (1997) 2079-2088
6. Sierra J., Pérez W.S., Rozman C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 100 (2002) 1997-2004
7. Rozman C., Giralt M., Feliu E., et al. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67 (1991) 2658-2663
8. Barosi G., Berzuini C., Liberato L.N., et al. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 70 (1988) 397-401
9. Dupriez B., Morel P., Demory J.L., et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88 (1996) 1013-1018
10. Onida F., Kantarjian H.M., Smith T.L., et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 99 (2002) 840-849
11. Thomas E.D. Bone marrow transplantation: a review. Semin Hematol 36 supplement 7 (1999) 95-103
12. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104 (2004) 579-585
13. Sorror M.L., Maris M.B., Storb R.F., et al. Hematopoietic cell transplantation (HCT)-specific-comorbidity index: a new tool for risk assessment before allogeneic HCT. Biol Blood Marrow Transplant 11 supplement 1 (2005) 23-24 [#67, 2005 (abstract)]
14. de Witte T., Suciu S., Verhoef G., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98 (2001) 2326-2331
15. Scott B.L., Storer B., Loken M., et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 11 (2005) 65-73
16. de Witte T., Zwaan F., Hermans J., et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol 74 (1990) 151-155
17. Appelbaum F.R., Barrall J., Storb R., et al. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Ann Intern Med 112 (1990) 590-597
18. Anderson J.E., Appelbaum F.R., Schoch G., et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14 (1996) 220-226
19. Anderson J.E., Anasetti C., Appelbaum F.R., et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol 93 (1996) 59-67
20. Demuynck H., Verhoef G.E., Zachee P., et al. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant 17 (1996) 745-751
21. Sutton L., Chastang C., Ribaud P., et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood 88 (1996) 358-365
22. Nevill T.J., Fung H.C., Shepherd J.D., et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92 (1998) 1910-1917
23. Runde V., de Witte T., Arnold R., et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic leukemia working party of the european group for blood and marrow transplantation. Bone Marrow Transplant 21 (1998) 255-261
24. Arnold R., de Witte T., van Biezen A., et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey, european blood and marrow transplantation group. Bone Marrow Transplant 21 (1998) 1213-1216
25. Deeg H.J., Shulman H.M., Anderson J.E., et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55-66 years of age. Blood 95 (2000) 1188-1194
26. de Witte T., Hermans J., Vossen J., et al. Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the chronic Leukaemia working party of the european group for blood and marrow transplantation (EBMT). Br J Haematol 110 (2000) 620-630
27. de Witte T., Pikkemaat F., Hermans J., et al. Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation. Leukemia 15 (2001) 1878-1884
28. Castro-Malaspina H., Harris R.E., Gajewski J., et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the national marrow donor program. Blood 99 (2002) 1943-1951
29. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 100 (2002) 1201-1207
30. Jurado M., Deeg H.J., Storer B., et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant 8 (2002) 161-169
31. Nevill T.J., Shepherd J.D., Reece D.E., et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 10 (1992) 445-450
32. Anderson J.E., Appelbaum F.R., Schoch G., et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood 87 (1996) 51-58
33. Copelan E.A., Penza S.L., Elder P.J., et al. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation. Bone Marrow Transplant 25 (2000) 1219-1222
34. Guardiola P., Runde V., Bacigalupo A., et al. Subcommittee for Myelodysplastic syndromes of the chronic Leukaemia working group of the european blood and marrow transplantation group: retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes. Blood 99 (2002) 4370-4378
35. Longmore G., Guinan E.C., Weinstein H.J., et al. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. J Clin Oncol 8 (1990) 1707-1714
36. Ratanatharathorn V., Karanes C., Uberti J., et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81 (1993) 2194-2199
37. O'Donnell M.R., Long G.D., Parker P.M., et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 13 (1995) 2973-2979
38. Mattijssen V., Schattenberg A., Schaap N., et al. Outcome of allogeneic bone marrow transplantation with lymphocyte-depleted marrow grafts in adult patients with myelodysplastic syndromes. Bone Marrow Transplant 19 (1997) 791-794
39. Okamoto S., Takahashi S., Wakui M., et al. Treatment of advanced myelodysplastic syndrome with a regimen including recombinant human granulocyte colony-stimulating factor preceding allogeneic bone marrow transplantation. Br J Haematol 104 (1999) 569-573
40. Hsu C., Lin M.T., Tang J.L., et al. Allogeneic stem cell transplantation for patients with high-risk myelodysplastic syndrome. J Formos Med Assoc 98 (1999) 157-164
41. Anderson J.E., Appelbaum F.R., Schoch G., et al. Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. Biol Blood Marrow Transplant 7 (2001) 163-170
42. Bibawi S., Abi-Said D., Fayad L., et al. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. Am J Hematol 67 (2001) 227-233
43. Bornhäuser M., Storer B., Slattery J.T., et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 102 (2003) 820-826
44. de Lima M., Couriel D., Thall P.F., et al. Once-daily intravenous buslfan and fludarabine: clinical and pharmacokinetic results of a myeloabltive, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104 (2004) 857-864
45. Singhal S., Powles R., Treleaven J., et al. Allogeneic bone marrow transplantation for primary myelofibrosis. Bone Marrow Transplant 16 (1995) 743-746
46. Guardiola P., Esperou H., Cazals-Hatem D., et al. French society of BMT: allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. Br J Haematol 98 (1997) 1004-1009
47. Anderson J.E., Sale G., Appelbaum F.R., et al. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 98 (1997) 1010-1016
48. Przepiorka D., Giralt S., Khouri I., et al. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases (Review). Am J Hematol 57 (1998) 24-28
49. van Besien K, Deeg HJ. Hemopoietic stem cell transplantation for myelofibrosis (Review). Semin Oncol; in press.
50. Guardiola P., Anderson J.E., Bandini G., et al. Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del midollo osseo, and Fred Hutchinson cancer research center collaborative study. Blood 93 (1999) 2831-2838
51. Deeg H.J., Gooley T.A., Flowers M.E.D., et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 102 (2003) 3912-3918
52. Platzbecker U., Gooley T., Anasetti C., et al. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. Leuk Lymphoma 43 (2002) 1409-1414
53. Zang D.Y., Deeg H.J., Gooley T., et al. Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation. Br J Haematol 110 (2000) 217-222
54. Kroger N., Zabelina T., Guardiola P., et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the chronic Leukaemia working party of the European group for blood and marrow transplantation (EBMT). Br J Haematol 118 (2002) 67-73
55. de Witte T., van Biezen A., Hermans J., et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 90 (1997) 3853-3857
56. Wattel E., Solary E., Leleu X., et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Leukemia 13 (1999) 524-529
57. Anderson J.E., Tefferi A., Craig F., et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. Blood 98 (2001) 586-593
58. Carella A.M., Champlin R., Slavin S., et al. Mini-allografts: ongoing trials in humans (Editorial). Bone Marrow Transplant 25 (2000) 345-350
59. Kroger N., Schetelig J., Zabelina T., et al. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone Marrow Transplant 28 (2001) 643-647
60. Martino R., Caballero M.D., Simón J.A., et al. AML and alloPBSCT subcommittees of the Spanish group for hematopoietic transplantation: evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 100 (2002) 2243-2245
61. Ho A.Y.L., Pagliuca A., Kenyon M., et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan and alemtuzumab (FBC) conditioning. Blood 104 (2004) 1616-1623
62. Stuart M.J., Cao T.M., Sandmaier B.M., et al. Efficacy of non-myeloablative allogeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (except chronic myelogenous leukemia). Blood 102 Part 1 (2003) 185a [#644, 2003 (abstract)]
63. Devine S.M., Hoffman R., Verma A., et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 99 (2002) 2255-2258
64. Rondelli D., Barosi G., Bacigalupo A., et al. Non-myeloablative allogeneic HSCT in high risk patients with myelofibrosis. Blood 102 (2003) 199a [abstract]
65. Alyea E., Kim H., Cutler C., et al. Similar outcome of non-myeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients greater than fifty years of age. Blood 104 Part 1 (2004) 89a [#300 (abstract)]
66. Scott B.L., Maris M., Sandmaier B., et al. Myeloablative versus nonmyeloablative hemopoietic cell transplantation (HCT) for patients with myelodysplasia (MDS) or AML with multinlineage dysplasia following MDS (tAML). Blood 104 Part 1 (2004) 638a [#2320 (abstract)]
67. Benesch M., and Deeg H.J. Hemopoietic cell transplantation for myelodysplastic syndromes. Curr Hematol Rep 2 (2003) 209-216
68. Wells D.A., Benesch M., Loken M.R., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood 102 (2003) 394-403
69. Maris M.B., Niederwieser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102 (2003) 2021-2030